XORTX Therapeutics Inc
XRTX
查看详细走势图
0.560USD
-0.016-2.74%
收盘 12/24, 13:00（美东）报价延迟15分钟
2.92M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.74%
5天
-4.22%
1月
-6.30%
6月
-30.14%
今年开始到现在
-50.40%
1年
-49.75%
查看详细走势图
TradingKey XORTX Therapeutics Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
XORTX Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
14.000
目标均价
+2058.50%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
XORTX Therapeutics Inc亮点
亮点风险
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
估值合理
公司最新PE估值-1.44，处于3年历史合理位
机构减仓
最新机构持股63.97K股，环比减少90.99%
XORTX Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
XORTX Therapeutics Inc简介
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
公司代码XRTX
公司XORTX Therapeutics Inc
CEODavidoff (Allen W)
网址https://www.xortx.com/
常见问题
XORTX Therapeutics Inc(XRTX)的当前股价是多少？
XORTX Therapeutics Inc(XRTX)的当前股价是 0.560。
XORTX Therapeutics Inc的股票代码是什么？
XORTX Therapeutics Inc的股票代码是XRTX。
XORTX Therapeutics Inc股票的52周最高点是多少？
XORTX Therapeutics Inc股票的52周最高点是2.490。
XORTX Therapeutics Inc股票的52周最低点是多少？
XORTX Therapeutics Inc股票的52周最低点是0.700。
XORTX Therapeutics Inc的市值是多少？
XORTX Therapeutics Inc的市值是2.92M。
XORTX Therapeutics Inc的净利润是多少？
XORTX Therapeutics Inc的净利润为-3.31M。
现在XORTX Therapeutics Inc(XRTX)的股票是买入、持有还是卖出？
根据分析师评级，XORTX Therapeutics Inc(XRTX)的总体评级为买入，目标价格为14.000。
XORTX Therapeutics Inc(XRTX)股票的每股收益（EPS TTM）是多少
XORTX Therapeutics Inc(XRTX)股票的每股收益（EPS TTM）是-0.400。
相关品种
